

assessment submitted with the petition that is the subject of this notice on public display at the Dockets Management Branch (address above) for public review and comment. Interested persons may, on or before June 19, 1995, submit to the Dockets Management Branch (address above) written comments. Two copies of any comments are to be submitted, except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Received comments may be seen in the office above between 9 a.m. and 4 p.m., Monday through Friday. FDA will also place on public display any amendments to, or comments on, the petitioner's environmental assessment without further announcement in the **Federal Register**. If, based on its review, the agency finds that an environmental impact statement is not required and

this petition results in a regulation, the notice of availability of the agency's finding of no significant impact and the evidence supporting that finding will be published with the regulation in the **Federal Register** in accordance with 21 CFR 25.40(c).

Dated: May 9, 1995.

**George H. Pauli**,  
*Acting Director, Office of Premarket Approval, Center for Food Safety and Applied Nutrition.*

[FR Doc. 95-12296 Filed 5-18-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 95N-0127]

**Roussel Corp., et al.; Withdrawal of Approval of 16 Abbreviated New Drug Applications**

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is withdrawing approval of 16 abbreviated new drug applications (ANDA's). The holders of the ANDA's notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

**EFFECTIVE DATE:** June 19, 1995.

**FOR FURTHER INFORMATION CONTACT:** Lola E. Batson, Center for Drug Evaluation and Research (HFD-360), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301-594-1038.

**SUPPLEMENTARY INFORMATION:** The holders of the ANDA's listed in the table in this document have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications. The applicants have also, by their request, waived their opportunity for a hearing.

ANDA no.	Drug	Applicant
62-830 .....	Sterile Cefazolin Sodium, U.S.P. (bulk) .....	Roussel Corp., 95 Chestnut Ridge Rd., P.O. Box 30, Montvale, NJ 07645.
70-662 .....	Diazepam Injection, U.S.P., 5 milligrams (mg)/milliliter (mL) ..	Fujisawa Pharmaceutical Co., Parkway North Center, Three Parkway North, Deerfield, IL 60015-2548.
80-517 .....	Prednisolone Sodium Phosphate Injection, U.S.P., 20 mg/mL	Steris Laboratories, Inc., 620 North 51st Ave., Phoenix, AZ 85043-4705.
80-702 .....	Vitamin A Palmitate Capsules, EQ 50,000 Units Base .....	Banner Pharmacaps, Inc., 1111 Jefferson Ave., Elizabeth, NJ 07207.
83-531 .....	Dimenhydrinate Injection, U.S.P., 50 mg/mL .....	Steris Laboratories, Inc.
83-593 .....	Chlorpheniramine Maleate Injection, U.S.P., 10 mg/mL .....	Do.
83-948 .....	Vitamin A Palmitate Capsules, EQ 50,000 Units Base .....	Banner Pharmacaps, Inc.
83-973 .....	Vitamin A Capsules, 50,000 U.S.P. Units .....	Do.
85-591 .....	Chlorpromazine Hydrochloride Injection, U.S.P., 25 mg/mL ...	Steris Laboratories, Inc.
86-419 .....	Testosterone Injection, U.S.P., 50 mg/mL .....	Do.
86-420 .....	Testosterone Injection, U.S.P., 25 mg/mL .....	Do.
86-468 .....	Procainamide Hydrochloride Extended-release Tablets, U.S.P., 250 mg.	Parke-Davis, Division of Warner-Lambert Co., 2800 Plymouth Rd., Ann Arbor, MI 48105.
86-844 .....	Acetic Acid Otic Solution with Hydrocortisone, 2%/1% .....	Procter & Gamble Pharmaceuticals, 11370 Reed Hartman Hwy. Cincinnati, OH 45241-2422.
86-845 .....	Acetic Acid Otic Solution, U.S.P., 2% .....	Do.
87-274 .....	Hydroxyzine Hydrochloride Injection, U.S.P., 25 mg/mL and 50 mg/mL.	Steris Laboratories, Inc.
88-642 .....	Diethylpropion Hydrochloride Tablets, U.S.P., 25 mg .....	Lemmon Co., 650 Cathill Rd., Sellersville, PA 18960.

Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the ANDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective June 19, 1995.

Dated: April 18, 1995.

**Murray M. Lumpkin**,  
*Deputy Director, Center for Drug Evaluation and Research.*

[FR Doc. 95-12295 Filed 5-18-95; 8:45 am]

BILLING CODE 4160-01-F

**Public Health Service**

**Agency Forms Undergoing Paperwork Reduction Act Review**

Each Friday the Public Health Service (PHS) publishes a list of information collection requests under review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the PHS Reports Clearance Office on (202) 690-7100.

The following requests have been submitted for review since the list was last published on May 12.

1. Studies of Adverse Reproductive Outcomes in Female Occupational Groups—New—The reproductive health of a group of female workers exposed to a particular environmental chemical agent will be compared to the reproductive health of a group of working women with no occupational exposure to known or suspected reproductive toxicants. Respondents: Individuals or households; Business or other for-profit. Send comments to Shannah Koss, Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503.